Creative Planning’s Nuvectis Pharma NVCT Stock Holding History

Creative Planning’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$295K	Buy	+13,985	New	+$295K	﹤0.01%	3665

Other funds holding NVCT

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Creative Planning's NVCT Position: Q3 2026 in Review

Creative Planning opened a new position in Nuvectis Pharma (NVCT) in Q3 2026: 13,985 shares worth $295K. The stake represents ﹤0.01% of the portfolio and ranks #3665 among its holdings.

20 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

Creative Planning held 13,985 shares of Nuvectis Pharma worth $295K as of Q3 2026.
Nuvectis Pharma was a new Creative Planning position in Q3 2026.
Nuvectis Pharma made up ﹤0.01% of Creative Planning's portfolio in Q3 2026, its #3665 holding.
20 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.